Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Hepatocellular Carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Published in 2018 – Ann Oncol (2018) 29 (Suppl 4): iv238–iv255.
Authors: A. Vogel, A. Cervantes, I. Chau, B. Daniele, J. Llovet, T. Meyer, J.-C. Nault, U. Neumann, J. Ricke, B. Sangro, P. Schirmacher, C. Verslype, C. J. Zech, D. Arnold & E. Martinelli, on behalf of the ESMO Guidelines Committee

A correction has been published - Annals of Oncology, mdy510
NB: The changes noted in the above correction have been incorporated into the manuscript displayed below. 

The 2018 ESMO Clinical Practice Guidelines on hepatocellular carcinoma (HCC) are conceived to provide the standard approach to diagnosis and local and systemic treatment of HCC. New recommendations are provided regarding the locoregional management and the systemic treatment with lenvatinib, regorafenib, cabozantinib, ramucirumab and the anti-PD-1 antibodies (nivolumab and pembrolizumab) for advanced HCC. Also included are new diagnosis systems and treatment algorithms.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.